Dendritic cells and malignant plasma cells: An alliance in multiple myeloma tumor progression?

Oncologist

Volumn 16, Issue 7, 2011, Pages 1040-1048

  Tucci, Marco ^a   Stucci, Stefania ^a   Strippoli, Sabino ^a   Dammacco, Franco ^a   Silvestris, Franco ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Bone disease; Dendritic cells; Immune system; Multiple myeloma

Indexed keywords

APRIL PROTEIN; ATACICEPT; BISPHOSPHONIC ACID DERIVATIVE; CATHEPSIN K; CD47 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR7; COLONY STIMULATING FACTOR 1; DENDRITIC CELL VACCINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; JANUS KINASE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN BCL XL; PROTEIN MCL 1; STAT3 PROTEIN; STROMAL CELL DERIVED FACTOR 1; THROMBOSPONDIN 1;

ANTIGEN PRESENTATION; ARTICLE; BONE DISEASE; CANCER CELL; CD8+ T LYMPHOCYTE; CELL MATURATION; CELL POLARITY; CELL PROLIFERATION; CELL TRANSDIFFERENTIATION; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; MOLECULAR INTERACTION; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PLASMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TH17 CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; UPREGULATION;

ANTIGEN-PRESENTING CELLS; DENDRITIC CELLS; DISEASE PROGRESSION; HUMANS; MULTIPLE MYELOMA; PLASMA CELLS;

EID: 79960880111     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0327     Document Type: Article

References (77)

1. Anderson KC, Shaughnessy JD, Barlogie B. et al. Multiple myeloma. He-matology Am Soc Hematol Educ Program 2002:214-240.
2. Mitsiades CS, McMillin DW, Klippel S et al. The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies. Hematol Oncol Clin North Am 2007;21:1007-1034, 7-8.
3. Hideshima T, Bergsagel PL, Kuehl WM et al. Advances in biology of multiple myeloma: Clinical applications. Blood 2004;104:607-618.
4. Munshi NC. Immunoregulatory mechanisms in multiple myeloma. Hema-tol Oncol Clin North Am 1997;11:51-69.
5. Hayashi T, Hideshima T, Akiyama M et al. Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes. Blood 2003;102:1435-1442.
6. Dhodapkar MV, Dhodapkar KM, Palucka AK. Interactions of tumor cells with dendritic cells: Balancing immunity and tolerance. Cell Death Differ 2008;15:39-50.
7. Hideshima T, Mitsiades C, Tonon G et al. Understanding multiple my-eloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007;7:585-598.
8. Steinman RM. Dendritic cells and the control of immunity: Enhancing the efficiency of antigen presentation. Mt Sinai J Med 2001;68:160-166.
9. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-252.
10. Dhodapkar MV, Krasovsky J, Olson K. T cells from the tumor microenvi-ronment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells. Proc Natl Acad SciU S A 2002;99:13009-13013.
11. Nouri-Shirazi M, Banchereau J, Bell D et al. Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses. J Immunol 2000;165:3797-3803.
12. Yi Q, Szmania S, Freeman J et al. Optimizing dendritic cell-based immunotherapy in multiple myeloma: Intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients. Br J Haematol 2010;150:554-564.
13. Brown RD, Pope B, Murray A et al. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-/31 and interleukin-10. Blood 2001;98:2992-2998.
14. Ratta M, Fagnoni F, Curti A et al. Dendritic cells are functionally defective in multiple myeloma: The role of interleukin-6. Blood 2002;100:230-237.
15. Ruffini PA, Biragyn A, Kwak LW. Recent advances in multiple myeloma immunotherapy. Biomed Pharmacother 2002;56:129-132.
16. Dhodapkar KM, Barbuto S, Matthews P et al. Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma. Blood 2008;112: 2878-2885.
17. Kukreja A, Radfar S, Sun BH et al. Dominant role of CD47-thrombospon-din-1 interactions in myeloma-induced fusion of human dendritic cells: Implications for bone disease. Blood 2009;114:3413-3421.
18. Cravens PD, Lipsky PE. Dendritic cells, chemokine receptors and autoimmune inflammatory diseases. Immunol Cell Biol 2002;80:497-505.
19. Chauhan D, Singh AV, Brahmandam M et al. Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: A therapeutic target. Cancer Cell 2009;16:309-323.
20. Kukreja A, Hutchinson A, Dhodapkar K. et al. Enhancement of clonogenic-ity of human multiple myeloma by dendritic cells. J Exp Med 2006;203: 1859-1865.
21. Silvestris F, Ciavarella S, De Matteo M et al. Bone-resorbing cells in multiple myeloma: Osteoclasts, myeloma cell polykaryons, or both? The Oncologist 2009;14:264-275.
22. Basak GW, Srivastava AS, Malhotra R et al. Multiple myeloma bone marrow niche. Curr Pharm Biotechnol 2009;10:345-346.
23. De Raeve HR, Vanderkerken K. The role of the bone marrow microenvi-ronment in multiple myeloma. Histol Histopathol 2005;20:1227-1250.
24. Mitsiades CS, Mitsiades NS, Munshi NC et al. The role of the bone mi-croenvironment in the pathophysiology and therapeutic management of multiple myeloma: Interplay of growth factors, their receptors and stromal interactions. Eur J Cancer 2006;42:1564-1573.
25. Bataille R, Jourdan M, Zhang XG et al. Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J Clin Invest 1989;84:2008-2011.
26. Ogata A, Chauhan D, Teoh G et al. IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J Immunol 1997;159: 2212-2221.
27. Jourdan M, Veyrune JL, De Vos J et al. A major role for Mcl-1 antiapop-totic protein in the IL-6-induced survival of human myeloma cells. Onco-gene 2003;22:2950-2959.
28. Chomarat P, Banchereau J, Davoust J et al. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat Immunol 2000;1: 510-514.
29. Bataille R, Chappard D, Alexandre C et al. Importance of quantitative histology of bone changes in monoclonal gammopathy. Br J Cancer 1986;53: 805-810.
30. Alsayed Y, Ngo H, Runnels J et al. Mechanisms of regulation of CXCR4/ SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood 2007;109:2708-2717.
31. Dieu MC, Vanbervliet B, Vicari A et al. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med 1998;188:373-386.
32. Rivollier A, Mazzorana M, Tebib J et al. Immature dendritic cell transdif-ferentiation into osteoclasts: A novel pathway sustained by the rheumatoid arthritis microenvironment. Blood 2004;104:4029-4037.
33. Maitra R, Follenzi A, Yaghoobian A et al. Dendritic cell-mediated in vivo bone resorption. J Immunol 2010;185:1485-1491.
34. Steinman RM. Dendritic cells and immune-based therapies. Exp Hematol 1996;24:859-862.
35. O'Doherty U, Peng M, Gezelter S et al. Human blood contains two subsets of dendritic cells, one immunologically mature and the other immature. Immunology 1994;82:487-493.
36. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006;6:24-37.
37. Almand B, Clark JI, Nikitina E et al. Increased production of immature myeloid cells in cancer patients: A mechanism of immunosuppression in cancer. J Immunol 2001;166:678-689.
38. Hàjek R, Butch AW. Dendritic cell biology and the application of dendritic cells to immunotherapy of multiple myeloma. Med Oncol 2000;17:2-15.
39. Raje N, Gong J, Chauhan D et al. Bone marrow and peripheral blood dendritic cells from patients with multiple myeloma are phenotypically and functionally normal despite the detection of Kaposi's sarcoma herpesvirus gene sequences. Blood 1999;93:1487-1495.
40. Lim SH, Wen YJ, Ling M. Malignancy: Idiotypic immune targeting ofmul-tiple myeloma. Hematology 2000;4:471-477.
41. Wen YJ, Ling M, Bailey-Wood R et al. Idiotypic protein-pulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma. Clin Cancer Res 1998;4:957-962.
42. Wen YJ, Ling M, Lim SH. Immunogenicity and cross-reactivity with idio-typic IgA of VH CDR3 peptide in multiple myeloma. Br J Haematol 1998; 100:464-468.
43. Campoli M, Ferrone S. HLA antigen changesinmalignant cells: Epigenetic mechanisms and biologic significance. Oncogene 2008;27:5869-5885.
44. Curti A, Tosi P, Comoli P et al. Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides. Br J Haematol 2007; 139:415-424.
45. Liso A, Stockerl-Goldstein KE, Auffermann-Gretzinger S et al. Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 2000;6:621-627.
46. Raje N, Hideshima T, Davies FE et al. Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma. Br J Haematol 2004;125:343-352.
47. Cook G, Campbell JD. Immune regulation in multiple myeloma: The host-tumour conflict. Blood Rev 1999;13:151-162.
48. Dhodapkar MV, Geller MD, Chang DH et al. A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J Exp Med 2003;197:1667-1676.
49. Lauria F, Foa R, Cavo M et al. Membrane phenotype and functional behaviour of T lymphocytes in multiple myeloma: Correlation with clinical stages of the disease. Clin Exp Immunol 1984;56:653-658.
50. Letterio JJ, Roberts AB. Regulation of immune responses by TGF-beta. Annu Rev Immunol 1998;16:137-161.
51. Schultze JL, Nadler LM. T cell mediated immunotherapy for B cell lymphoma. J Mol Med 1999;77:322-331.
52. Steinbrink K, Wölfl M, Jonuleit H et al. Induction of tolerance by IL-10-treated dendritic cells. J Immunol 1997;159:4772-4780.
53. Podar K, Richardson PG, Hideshima T et al. The malignant clone and the bone-marrow environment. Best Pract Res Clin Haematol 2007;20:597-612.
54. Menetrier-Caux C, Montmain G, Dieu MC et al. Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: Role of interleukin-6 and macrophage colony-stimulating factor. Blood 1998;92: 4778-4791.
55. Yang L, Carbone DP. Tumor-host immune interactions and dendritic cell dysfunction. Adv Cancer Res 2004;92:13-27.
56. Nefedova Y, Nagaraj S, Rosenbauer A et al. Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the Janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Res 2005;65:9525-9535.
57. Nosaka T, Kitamura T. Janus kinases (JAKs) and signal transducers and activators of transcription (STATs) in hematopoietic cells. Int J Hematol 2000;71:309-319.
58. Fricke I, Gabrilovich DI. Dendritic cells and tumor microenvironment: A dangerous liaison. Immunol Invest 2006;35:459-483.
59. Park SJ, Nakagawa T, Kitamura H et al. IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation. J Immunol 2004;173:3844-3854.
60. García De Vinuesa C, Gulbranson-Judge A, Khan M et al. Dendritic cells associated with plasmablast survival. Eur J Immunol 1999;29:3712-3721.
61. Della Bella S, Gennaro M, Vaccari M et al. Altered maturation of peripheral blood dendritic cells in patients with breast cancer. Br J Cancer 2003;89: 1463-1472.
62. Mundy GR. Myeloma bone disease. Eur J Cancer 1998;34:246-251.
63. Abe M, Hiura K, Wilde J et al. Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: A vicious cycle between bone destruction and myeloma expansion. Blood 2004;104:2484-2491.
64. Farrugia AN, Atkins GJ, To LB et al. Receptor activator of nuclear fac-tor-KB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Res 2003;63:5438-5445.
65. Takayanagi H. Osteoimmunology: Shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 2007;7:292-304.
66. Alnaeeli M, Park J, Mahamed D et al. Dendritic cells at the osteo-immune interface: Implications for inflammation-induced bone loss. J Bone Miner Res 2007;22:775-780.
67. Wakkach A, Mansour A, Dacquin R et al. Bone marrow microenvironment controls the in vivo differentiation of murine dendritic cells into osteoclasts. Blood 2008;112:5074-5083.
68. Tucci M, Stucci S, Strippoli S et al. Cytokine overproduction, T-cell activation, and defective T-regulatory functions promote nephritis in systemic lupus erythematosus. J Biomed Biotechnol 2010:2010:457146.
69. Kryczek I, Banerjee M, Cheng P et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 2009;114:1141-1149.
70. de Beaucoudrey L, Puel A, Filipe-Santos O et al. Mutations in STAT3 and IL12RB1 impair the development of human IL-17-producing T cells. J Exp Med 2008;205:1543-1550.
71. Kotake S, Udagawa N, Takahashi N et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogen-esis. J Clin Invest 1999;103:1345-1352.
72. Giuliani N, Lisignoli G, Colla S et al. CC-Chemokine ligand 20/macro-phage inflammatory protein-3a and CC-chemokine receptor 6 are overex-pressed in myeloma microenvironment related to osteolytic bone lesions. Cancer Res 2008;68:6840-6850.
73. Ouyang W, Filvaroff E, Hu Y et al. Novel therapeutic targets along the Th17 pathway. Eur J Immunol 2009;39:670-675.
74. Rossi JF, Moreaux J, Hose D et al. Atacicept in relapsed/refractory multiple myeloma or active Waldenstrom's macroglobulinemia: A phase I study. Br J Cancer 2009;101:1051-1058.
75. Henry DH, Costa L, Goldwasser F et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011;29:1125-1132.
76. Eisman JA, Bone HG, Hosking DJ et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three-year continued therapy and resolution of effect. J Bone Miner Res 2011;26:242-251.
77. Araujo JC, Poblenz A, Corn P et al. Dasatinib inhibits both osteoclast activation and prostate cancer PC-3-cell-induced osteoclast formation. Cancer Biol Ther 2009;8:2153-2159.